Digoxin prevents breast cancer metastases in a new study
The active ingredient digoxin, a substance found in foxglove, reduces the number of cells in clusters of breast cancer cells circulating in the blood, new research has found.
These clusters are responsible for the formation of metastases in other organs. The smaller the clusters, the fewer metastases can form. This means that the active ingredient could complement other cancer drugs that fight the primary tumour.
Certain tumour types continuously release circulating tumour cells (CTCs) into the blood, which join together into small clusters, settle in other organs and form metastatic tumours.
In breast cancer, as soon as the primary tumour forms metastases, the chances of survival decrease drastically.
In the new study, which has been published in the journal Nature Medicine, a team of researchers from ETH Zurich, the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital, show a promising new approach.
The researchers administered the drug digoxin at a low and safe dosage for one week to nine patients with metastatic breast cancer.
The number of cells per cluster decreased significantly – by an average of 2.2 cells. Given that typical cluster sizes are only a handful of cells, this means a significant reduction in the risk of metastases.
Dissolving clusters of cancer cells
The Achilles’ heel of CTC clusters are the sodium-potassium pumps (also known as Na+/K+-ATPases), which are located in the membranes of tumour cells and are responsible for transporting sodium out of the cells and potassium into them.
Digoxin blocks these ion pumps and thus suppresses the ion exchange. The cells therefore absorb more calcium from the outside of the cell membrane. This weakens the cohesion of the cancer cells in the cluster, causing them to fall apart.
However, the researchers emphasise that digoxin alone does not eliminate the existing tumour. The agent would have to be administered in combination with other substances that kill existing cancer cells.
More effective new molecules based on digoxin are currently under development by ETH spin-out Page Therapeutics.
Diana Spencer, Senior Digital Content Editor, DDW
